KYU-SUNG LEE: Clinical Trials

5 trials sponsored by KYU-SUNG LEE, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 3 Phase 4, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 43Completed 3
Not applicable2Completed 2

Follow KYU-SUNG LEE: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia
Holmium Laser Enucleation of the Prostate (HoLEP), Holmium laser enucleation system and morcellator - Benign Prostatic Hypertrophy With Outflow Obstruction, Overactive Detrusor
Not applicableCompletedKYU-SUNG LEE1842013-02-012019-12-02
A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks
Solifenacin - Overactive Bladder
Phase 4CompletedKYU-SUNG LEE3072009-03-012016-01-07
A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder
Alpha blocker, placebo, solifenacin - Urinary Bladder, Overactive
Phase 4CompletedKYU-SUNG LEE942008-06-012016-01-07
Efficacy and Safety of Extracorporeal Biofeedback
PFMT with Extracorporeal Biofeedback - Female Stress Urinary Incontinence
Not applicableCompletedKYU-SUNG LEE1002007-07-012019-12-02
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Tolterodine, Tolterodine 6 - Overactive Bladder
Phase 4CompletedKYU-SUNG LEE1732006-08-012019-12-02

Conditions studied

Urinary Bladder, Overactive (4)

Interventions

Solifenacin Succinate (2)  ·  Adrenergic alpha-Antagonists (1)  ·  Tolterodine Tartrate (1)

Countries

South Korea (5)

Results publications

PMID 25363606